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Background 
The Trinder reaction brought indisputable benefits to the clinical laboratory analysis providing specific and precise measurement of 
several clinical markers. However, multiple recent studies showed chemical interferences in Trinder reaction based analyses such as 
creatinine, triglycerides, uric acid and cholesterol tests, that significantly alter laboratory results. The aim of this study was to 
quantify interference effects of six widely prescribed drugs with analytical methods utilizing the Trinder chromogenic reaction. 
Material and methods: 
Samples were prepared by spiking a pooled blood plasma with the specific medical solution (original values listed in tab. 1). The 
first set of samples was prepared with therapeutic concentrations of six drugs: 
 ACC® (N-acetylcysteine; 875 mg/L = 5.36 mmol/L; fig. 1)  
 Novalgin® (metamizole; 150 mg/L = 0.48 mmol/L; fig. 2)  
 Dobutamin Admeda® (dobutamine; 400 µg/L = 1.33 µmol/L; fig. 3)   
 Dicynone® (etamsylate; 50 mg/L = 0.19 mmol/L; fig. 4)  
 Tensamin® (dopamine; 75 µg/L = 0.49 µmol/L; fig. 5)  
 Ascorbic acid (25 mg/L = 0.14 mmol/L; fig. 6) 
The second set of samples was prepared with unified concentration of 1 mmol/L drug per sample. The results of cholesterol, creatinine, 
triacylglycerides and uric acid were compared to the values obtained from the pooled plasma with physiological solution addition. The 
analysis was performed in University Hospital Brno with the C8000 c702 (Roche) analyzer with the reagent sets of cholesterol (CHOL2), 
creatinine (CREP2), uric acid (UA2) and triacylglycerides (TRIGL) by Roche company. 
Results 
Significant interference occurred in three out of the six samples 
with therapeutic concentration of drugs (fig. 7). ACC® 
(cholesterol -54.2%, creatinine -33.3%, triacylglycerides -83.3%, 
uric acid -22.1%), Dicynone® (creatinine -54.3%, 
triacylglycerides -24.6%, uric acid -21.0%) and Novalgin® 
(creatinine -28.4%, triacylglycerides -15.9%, uric acid -10.7%). 
The interference in samples containing 1 mmol/L drug 
concentration showed in all of the samples (fig. 8) and most 
prominently in Dobutamine  Admeda® (cholesterol -52.1%, 
creatinine -39.5%, triacylglycerides -89.7%, uric acid -83.0%), 
Tensamin® (cholesterol -39.6%, creatinine -85.2%, 
triacylglycerides -81.7%, uric acid -86.1%) and Dicynone® 
(cholesterol -16.7%, creatinine -81.5%, triacylglycerides -69.8%, 
uric acid -56.9%). The effective molecules have similar 
hydroquinone structure, which may enable us to predict the risk 
of interference in drugs of the same type. 
Conclusions 
This study shows how significantly are common medications 
able to alter the measurement results. Even though some 
information of these interferences were available in the past, 
their acknowledgement in the field of laboratory medicine is still 
low. This may be fixed by the application of sophisticated 
software informing doctors of a known interfering substance. 
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Fig. 4: Etamsylate (Dicynone®) Fig. 2: Metamizole (Novalgin®) 
Fig. 5: Dopamine (Tensamin®) Fig. 6: Ascorbic acid 
Fig. 3: Dobutamine (Dobutamine Admeda®) 
Uric acid Creatinine Triacylglycerides Cholesterol 
[µmol/L] [µmol/L] [mmol/L] [mmol/L] 
290 81 1.26 4.8 
Tab. 1: Pooled blood plasma original values 





















Therapeutic drug concentration interference 
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Fig. 7: Decrease of method recovery for individual analytes with each of six drugs in their therapeutic concentrations. 
Fig. 1: N-acetylcysteine (ACC®) 
Fig. 8: Decrease of method recovery for individual analytes with each of six drugs in their 1 mmol/l concentrations. 
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